Absence of nalbuphine anti-analgesia in the rat
- PMID: 12842282
- DOI: 10.1016/s0304-3940(03)00538-x
Absence of nalbuphine anti-analgesia in the rat
Abstract
In humans, kappa agonist-antagonist opioids such as nalbuphine have been proposed to produce both analgesia and anti-analgesia by acting at distinct receptors. The anti-analgesia appears to be greater in men, which may contribute to the greater nalbuphine analgesia observed in women. Kappa agonist-antagonists are also known to produce sexually dimorphic antinociception in nonhuman species but are generally more potent in males; anti-analgesia has not been reported in animals. The aim of the present study was to determine if nalbuphine anti-analgesia can be detected in the rat. Since nalbuphine anti-analgesia is more sensitive to naloxone antagonism than its analgesic effect, low doses of naloxone were combined with nalbuphine. Using the Randall-Selitto paw-withdrawal test, nalbuphine (0.5-10 mg/kg) induced dose-dependent antinociception in the rat. The antinociceptive effect of nalbuphine (0.5 or 1 mg/kg) was not enhanced by lower doses of naloxone but was antagonized by higher doses. These data do not support the hypothesis that the naloxone-sensitive anti-analgesic effect of nalbuphine observed in humans is present in the rat and could explain, at least in part, the opposite direction of the sex differences for kappa agonist-antagonist opioid analgesia observed in these two species.
Similar articles
-
NOP receptor mediates anti-analgesia induced by agonist-antagonist opioids.Neuroscience. 2014 Jan 17;257:139-48. doi: 10.1016/j.neuroscience.2013.10.061. Epub 2013 Nov 1. Neuroscience. 2014. PMID: 24188792 Free PMC article.
-
Dose ratio is important in maximizing naloxone enhancement of nalbuphine analgesia in humans.Neurosci Lett. 2003 Nov 6;351(1):5-8. doi: 10.1016/s0304-3940(03)00939-x. Neurosci Lett. 2003. PMID: 14550900 Clinical Trial.
-
A subanalgesic dose of morphine eliminates nalbuphine anti-analgesia in postoperative pain.J Pain. 2008 Apr;9(4):337-41. doi: 10.1016/j.jpain.2007.11.011. Epub 2008 Jan 16. J Pain. 2008. PMID: 18201935 Free PMC article.
-
Nalbuphine.Drug Alcohol Depend. 1985 Feb;14(3-4):339-62. doi: 10.1016/0376-8716(85)90066-3. Drug Alcohol Depend. 1985. PMID: 2986929 Review.
-
Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.Drug Res (Stuttg). 2016 Nov;66(11):562-570. doi: 10.1055/s-0042-109393. Epub 2016 Aug 9. Drug Res (Stuttg). 2016. PMID: 27504867 Review.
Cited by
-
Sex differences in kappa opioid pharmacology.Life Sci. 2011 Jan 3;88(1-2):2-16. doi: 10.1016/j.lfs.2010.10.007. Epub 2010 Oct 14. Life Sci. 2011. PMID: 20951148 Free PMC article. Review.
-
Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.J Am Assoc Lab Anim Sci. 2017 Sep 1;56(5):534-538. J Am Assoc Lab Anim Sci. 2017. PMID: 28903824 Free PMC article. Clinical Trial.
-
A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain.J Pharmacokinet Pharmacodyn. 2008 Feb;35(1):69-83. doi: 10.1007/s10928-007-9076-y. Epub 2007 Oct 18. J Pharmacokinet Pharmacodyn. 2008. PMID: 17943420 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources